⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Haisco Pharmaceutical Group Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Haisco Pharmaceutical Group Co., Ltd.
↗Shannan, China
Haisco Pharmaceutical Group is a diversified, publicly traded Chinese pharmaceutical company established in 2000. It integrates R&D, manufacturing, and sales, with a strong focus on innovative drug development in areas including oncology, CNS, metabolic, and cardiovascular diseases.
The company is a significant player in the Chinese market, particularly in parenteral nutrition and liver disease treatments. Haisco maintains a robust R&D pipeline and has expanded its global footprint through subsidiaries like Haisco-USA, focusing on international drug development and strategic collaborations with global pharmaceutical leaders.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Oncology, CNS, and Specialty Pharmaceuticals
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$712M
Founded:2000
Ownership:public
Status:operating
STOCK
Exchange:SZ Stock Exchange
Ticker:002653
Market Cap:$10.9B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Haisco-USA Pharmaceuticals, Inc.
Key Partnerships:Eli Lilly and Company (June 2026 collaboration for innovative medicine development)
COMPETITION
Position:Challenger
LEADERSHIP
Key Executives:
Xiu Lian Fan - CEO
Jun Min Wang - Chairman
Pangke Yan - GM & Director
LINKS
Website:haisco.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Haisco Pharmaceutical Group Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.